Adolescent pregnancy at antiretroviral therapy (ART) initiation: a critical barrier to retention on ART

Harriet Nuwagaba-Biribonwoh1,2, Agnes N Kiragga3, Constantin T Yiannoutsos4, Beverly S Musick5, Kara K Wools-Kaloustian6, Samuel Ayaya6, Hilary Wolf7, Emmanuel Lugina8, John Ssali9, Elaine J Abrams1,2,10 and Batya Elul2 for the International epidemiology Databases to Evaluate AIDS (IeDEA) East Africa Collaboration

Abstract
Introduction: Adolescence and pregnancy are potential risk factors for loss to follow-up (LTFU) while on antiretroviral therapy (ART). We compared adolescent and adult LTFU after ART initiation to quantify the impact of age, pregnancy, and site-level factors on LTFU.

Methods: We used routine clinical data for patients initiating ART as young adolescents (YA; 10 to 14 years), older adolescents (OA; 15 to 19 years) and adults (≥20 years) from 2000 to 2014 at 52 health facilities affiliated with the International epidemiology Databases to Evaluate AIDS (IeDEA) East Africa collaboration. We estimated cumulative incidence (95% confidence interval, CI) of LTFU (no clinic visit for ≥6 months after ART initiation) and identified patient and site-level correlates of LTFU, using multivariable Cox proportional hazards models for all patients as well as individual age groups.

Results: A total of 138,387 patients initiated ART, including 2496 YA, 2955 OA and 132,936 adults. Of these, 55%, 78% and 66%, respectively, were female and 0.7% of YA, 22.3% of OA and 8.3% of adults were pregnant at ART initiation. Cumulative incidence of LTFU at five years was 26.6% (24.6 to 28.6) among YA, 44.1% (41.8 to 46.3) among OA and 29.3% (29.1 to 29.6) among adults. Overall, compared to adults, the adjusted hazard ratio, aHR, (95% CI) of LTFU for OA was 1.54 (1.41 to 1.68) and 0.77 (0.69 to 0.86) for YA. Compared to males, pregnant females had higher hazard of LTFU, aHR 1.20 (1.14 to 1.27), and nonpregnant women had lower hazard aHR 0.90 (0.88 to 0.93). LTFU hazard among the OA was primarily driven by both pregnant and nonpregnant females, aHR 2.42 (1.98 to 2.95) and 1.51 (1.27 to 1.80), respectively, compared to men. The LTFU hazard ratio varied by IeDEA program. Site-level factors associated with overall lower LTFU hazard included receiving care in tertiary versus primary-care clinics aHR 0.61 (0.56 to 0.67), integrated adult and adolescent services and food ration provision aHR 0.93 (0.89 to 0.97) versus nonintegrated clinics with food ration provision, having patient support groups aHR 0.77 (0.66 to 0.90) and group adherence counselling aHR 0.61 (0.57 to 0.67).

Conclusions: Older adolescents experienced higher risk of LTFU compared to YA and adults. Interventions to prevent LTFU among older adolescents are critically needed, particularly for female and/or pregnant adolescents.

Keywords: antiretroviral therapy (ART); pregnancy; adolescents; Africa; ART retention; HIV outcomes

1 | INTRODUCTION

Nearly two million adolescents (10 to 19 years) are living with HIV in sub-Saharan Africa, the most significantly HIV impacted region of the world [1]. Due to the anticipated increase in absolute population numbers of adolescents and youth 15 to 24 years, called the youth bulge [2], the number of new HIV infections among adolescents is expected to increase by 2030 [1], making this a critically important group to focus on in the HIV response. The use of antiretroviral (ART) therapy is associated with less morbidity and mortality among persons living with HIV (PLHIV), and declining mortality trends have been observed with ART scale-up globally [3]. However, loss to follow-up (LTFU) after ART initiation can potentially reverse these gains.

Some studies have compared rates of LTFU after ART initiation between adolescents and youth, and adults with mixed results: some have reported higher LTFU among the adolescents compared to adults [4], while others showed similar or better outcomes [5-7]. However, these studies were limited by inadequate disaggregation of the adolescent age group. Adolescents (10 to 19 years) represent a mix of both a younger (10 to 14 years) and older (15 to 19 years) population, who are at different developmental stages and may have vastly different family support and patterns of accessing health care. This may in turn drive different ART retention
behaviours. A better understanding of the ART retention patterns of younger and older adolescents is needed in order to appropriately target retention interventions.

Additionally, pregnancy at ART initiation is increasingly being associated with high LTFU after ART initiation in multiple cohorts, particularly as countries adopt lifelong ART for pregnant and breastfeeding women (Option B+) [8-12]. Reasons for this may include individual factors related to child care, relationships with partners and family, migration postdelivery, stigma, and social barriers [13]. Additionally, structural barriers such as limited access to services, limited integration of ART in postnatal services and other health system challenges may impact ART retention [13]. These barriers are likely to be amplified among pregnant adolescents. To date, there is limited exploration of the impact of pregnancy on LTFU among adolescents who initiate ART.

In order to explore and quantify the impact and interactions between age, pregnancy, and site-level factors on LTFU among adolescents initiating ART in East Africa, we undertook a multicountry analysis which compared the rates and factors associated with LTFU among young adolescents (YA, 10 to 14 years), older adolescents (OA, 15 to 19 years) and adults (20 years and older).

2 | METHODS

2.1 | Study design

We conducted a retrospective cohort analysis of routinely collected clinical data from patients initiating ART at health facilities affiliated with the East Africa region of the International epidemiology Databases to Evaluate AIDS (IeDEA) collaboration [14]. This study was approved by the Indiana and Columbia University Institutional Review Boards (IRBs) and all regulatory bodies affiliated with the sites contributing data through mid to late 2014. A structured site assessment was completed at each site in 2009 and 2014, and gathered information on location and type of clinic, as well as the type of services offered [15].

2.2 | Study population

Individual patient-level data were included in this analysis if the patient was treatment naïve at enrolment, initiated ART between February 2000 and December 2014 and was at least 10 years of age at ART initiation. Women initiating ART solely for prevention of mother-to-child transmission of HIV (PMTCT) rather than for clinical indications were excluded from this analysis. Based on the age of ART initiation, age groups were defined as young adolescents (10 to 14 years), older adolescents (15 to 19 years) or adults (≥20 years).

2.3 | Setting and standard of care

A total of 52 health facilities representing six programmes in Kenya, Tanzania, and Uganda were included in this analysis. These sites represented a mixture of private and public facilities; primary, secondary and tertiary levels of care; and urban and rural healthcare facilities. In most sites, adolescents and adults were seen in the same clinic. However, models of service delivery varied by site [15]. Clinical care was provided in accordance with local or national guidelines which were generally consistent with the WHO guidelines of the period. At enrolment, adolescents and adults were assessed for ART eligibility based on clinical stage (WHO/CDC) and CD4 criteria. Prior to 2011, the criteria for ART initiation were based on variations of the 2006 WHO treatment guidelines [16]; all patients with CD4 count <200 cells/µL or WHO Stage 4, pregnant women at CD4 count <350 cells/µL and WHO Stage 3; with one programme treating all individuals with WHO stage 3 or 4 disease. From 2011 onwards, health facilities gradually adopted the 2010 WHO treatment guidelines recommending that all patients (including pregnant women) with a CD4 count <350 cells/µL or WHO Stage 3 or 4 be initiated on ART. The exception was the Academic Model Providing Access to Healthcare (AMPATH) western Kenya programme, which utilized a CD4 count threshold of 500 cells/µL for 10 to 14 year olds during this period.

2.4 | Data collection and management

As part of routine clinical care, patient characteristics (age, sex) and clinical status (WHO stage, CD4 count), ART regimen and outcomes (e.g. transfer out, LTFU and death) were captured on paper-based forms at enrolment and follow-up visits. Data clerks within the programme entered these data into a site-specific electronic medical record system and conducted quality and logic checks following standardized local data cleaning protocols. Data were deidentified and merged across sites by IeDEA East Africa regional data managers who performed additional data cleaning and validation. The date of database closure varied with three sites leaving the IeDEA consortium during the latter half of 2010, one site contributing data through March 2012, and the remaining sites contributing data through mid to late 2014. A structured site assessment was completed at each site in 2009 and 2014, and gathered information on location and type of clinic, as well as the type of services offered [15].

2.5 | Data analysis

The outcome of interest was LTFU following ART initiation. Patients were considered LTFU if they did not have a clinic visit for ≥6 months prior to database closure and were not documented as having died (mortality) or transferred out. Patients who had no return visit after ART initiation were randomly imputed days of follow-up between one and fourteen days, to allow for inclusion of their data in the survival analysis. The imputation model followed a simple uniform distribution for the days of follow-up. The patient-level variables of interest were age, CD4 count and WHO stage, calendar year and pregnancy status, all at ART initiation. Using age at ART initiation, patients were categorized as young adolescents 10 to 14 years (YA), older adolescents 15 to 19 years (OA) or adults ≥20 years. CD4 count at ART initiation was defined as the most proximal CD4 count obtained within three months prior to ART initiation and up to seven days after. WHO stage at ART start was defined as the maximum WHO stage documented prior to ART initiation or the first documented within 60 days after the start of treatment. In a number of cases, CDC class was used to reflect disease severity. This was mapped to WHO stage in these analyses as follows: CDC class N→WHO stage 1, A→2, B→3 and C→4. Pregnancy at
ART initiation was defined as a recorded pregnancy within two months before or after ART initiation date; or a documented estimated or actual date of delivery (according to available data) which resulted in an actual or estimated date of conception which in turn identified a pregnancy prior to ART-initiation.

We compared demographic characteristics by age group using descriptive statistics. We estimated the cumulative incidence of LTFU, using the Aalen & Johansen estimator which accounts for competing risks [18], considering mortality as a competing risk. Estimates were provided at six months and annually for five years, in line with routine progress review time points. The effect of patient-level and site-level factors on LTFU after ART initiation was assessed using cause-specific hazards models, with censoring at the time of death or the end of follow-up. Site-level variables such as level of care, location of health facility, support services offered and type of programme were included in order to control for unmeasured factors within each model of health service delivery, and generate adjusted hazard ratios (aHR) for LTFU after ART initiation. Models were run for all patients and then individually by age group. All patient- and site-level variables described above were introduced in multivariable models and variables significant at the 5% level were retained. All analyses were performed using STATA 14.2 (Stata-corp, College Station, TX, USA).

### RESULTS

Between 2000 and 2014, 211,362 patients age 10 and older were enrolled into East Africa programs, of whom

| Variable | Young adolescents (10 to 14 years) \(N = 2496\) | Older adolescents (15 to 19 years) \(N = 2955\) | Adults (20+ years) \(N = 132,936\) |
|----------|--------------------------------------|--------------------------------------|--------------------------------------|
| Country, n (%) | | | |
| Kenya | 2069 (82.9) | 2376 (80.4) | 106,292 (80.0) |
| Tanzania | 174 (7.0) | 137 (4.6) | 9093 (6.8) |
| Uganda | 253 (10.1) | 442 (15.0) | 17,551 (13.2) |
| Female sex, n (%) | | | |
| Male | 1364 (54.7) | 2300 (77.8) | 87,950 (66.2) |
| Pregnant at ART initiation | 17 (1.2) | 658 (22.3) | 11,054 (8.3) |
| Gender and pregnancy status | | | |
| Males | 1132 (45.3) | 655 (22.2) | 44,986 (33.8) |
| Nonpregnant females | 1347 (54.0) | 1642 (55.6) | 76,896 (57.8) |
| Pregnant females | 17 (0.7) | 658 (22.3) | 11,054 (8.3) |
| Age: ART start, years | | | |
| Median (IQR) | 12.5 (11.4–13.7) | 18.3 (16.9–19.3) | 35.8 (29.8–43.3) |
| CD4 cell count at ART start, cells/μL: median (IQR) | 186 (56–343) | 216 (85–387) | 154 (67–252) |
| CD4 cell count at ART start, cells/μL | | | |
| <100 | 559 (22.4) | 529 (17.9) | 31,461 (23.7) |
| 100 to 199 | 312 (12.5) | 361 (12.2) | 26,367 (19.8) |
| 200 to 349 | 390 (15.6) | 461 (15.6) | 22,988 (17.3) |
| ≥350 | 406 (16.3) | 542 (18.3) | 10,135 (7.6) |
| Missing | 829 (33.2) | 1062 (35.9) | 41,985 (31.6) |
| WHO stage at ART start | | | |
| I/II | 476 (19.1) | 842 (28.5) | 57,688 (43.4) |
| III/IV | 549 (22.0) | 1678 (56.8) | 63,947 (48.1) |
| Missing | 1471 (58.9) | 435 (14.7) | 11,301 (8.5) |
| WHO/CDC stage at ART start | | | |
| III/IV/B/C | 1141 (45.7) | 911 (30.8) | 57,691 (43.4) |
| I/II/N/S | 944 (37.8) | 1697 (57.4) | 63,944 (48.1) |
| Missing | 411 (16.5) | 347 (11.7) | 11,301 (8.5) |
| Year of ART initiation | | | |
| 2000 to 2004 | 109 (4.4) | 77 (2.6) | 4819 (3.6) |
| 2005 to 2009 | 1081 (43.3) | 914 (30.9) | 59,004 (44.4) |
| 2010 to 2012 | 888 (35.6) | 1087 (36.8) | 45,434 (34.2) |
| 2013 to 2014 | 418 (16.8) | 877 (29.7) | 23,679 (17.8) |

IeDEA, International epidemiology Databases to Evaluate AIDS; IQR, inter-quartile range.
138,387 (65.5%) initiated ART. Of these, 2496 (1.8%) were YA, 2955 (2.1%) were OA and 132,936 (96.1%) were adults. The majority of patients starting ART were female, including 54.7% of YA, 77.8% OA and 66.2% adults (Table 1). The median age (inter-quartile range (IQR)) at ART initiation was 12.5 years (IQR 11.4 to 13.7) among YA, 18.3 years (IQR 16.9 to 19.3) among OA and 35.8 years (IQR 29.8 to 43.3) among adults. CD4 counts at ART initiation were available for 66.8% of YA, 64.1% of OA and 68.4% of adults, with a median CD4 count of 186 cells/µL (IQR 56–343), 216 cells/µL (IQR 85 to 387) and 154 cells/µL (IQR 67 to 252) for YA, OA and adults, respectively. Of the total population initiating ART, pregnancy at ART initiation was documented in 0.7% of YA, 22.3% OA and 8.3% adults. The majority of patients were enrolled in the AMPATH program. Distribution of the study population by site characteristics among YA, OA and adults was similar (Table 2). Half the health facilities in this analysis were primary health facilities (50.0%), and nearly half (42.3%) offered combined adolescent and adult services.
3.1 | Cumulative incidence of LTFU after ART initiation

The cumulative incidence of LTFU was highest among OA (Figure 1). At six months after ART initiation, 18.4% (95% confidence interval (CI) 17.0 to 19.8) of OA were lost to follow-up, compared to 9.5% (95% CI 8.4 to 10.7) of YA and 12.0% (95% CI 11.8 to 12.2) of adults. Cumulative incidence of LTFU after ART initiation at 5 years was 26.6% (24.6 to 28.6) among YA, 44.1% (41.8 to 46.3) among OA and 29.3% (29.1 to 29.6) among adults (Figure 1).

3.2 | Correlates of LTFU after ART initiation

Thirty three of the 52 sites involved in this study had available site-level data and their patients were included in these analyses, which represented 94.6% of patients within this dataset. In the multivariable model for the overall study population, the adjusted cause-specific hazard ratio (aHR) of LTFU among OA was 1.54 (95% CI 1.41 to 1.68) (Table 3). By contrast, the hazard of LTFU was lower among YA compared to adults (aHR 0.77, 95% CI 0.69 to 0.86). When compared to men, the hazard of being LTFU was 10% lower among non-pregnant women (aHR 0.90, 95% CI 0.88 to 0.93) but 20% higher among pregnant women (aHR 1.20, 95% CI 1.14 to 1.27). In addition, more recent year of ART start was associated with a higher hazard of LTFU. Patients with CD4 counts between 100 and 199 and 200 and 350 cells/µL had lower rates of LTFU compared to patients with CD4 count ≥350 cells/µL (aHR 0.86, 95% CI 0.81 to 0.90 and 0.82, 95% CI 0.77 to 0.86, respectively), while WHO stage 3 or 4 was associated with a 32% increased hazard of LTFU (aHR 1.32, 95% CI 1.28 to 1.36). Compared to participants who initiated ART in 2000 to 2004, aHR for LTFU among participants who initiated ART in 2010 to 2012 and 2013 to 2014 were 1.27 (95% CI 1.17 to 1.39) and 1.19 (95% CI 1.06 to 1.32), respectively.

The hazard of LTFU in the overall study population varied widely among leDEA programs. In comparison to the largest programme (AMPATH), all other programmes had lower hazard of LTFU, except the Tanzania NACP programme (aHR 3.49, 95% CI 3.02 to 4.03) (Table 3). Other site-level factors

| Years after ART initiation | Cumulative incidence of LTFU (95% confidence interval) | Cumulative incidence of LTFU (95% confidence interval) | Cumulative incidence of LTFU (95% confidence interval) | Cumulative incidence of LTFU (95% confidence interval) |
|---------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| 0.5 years                 | 9.5 ( 8.4–10.7)                                       | 18.4(17.0–19.8)                                       | 12.0 (11.8–12.2)                                      | 12.1 (11.9–12.3)                                      |
| 1 year                    | 12.4(11.1–13.7)                                      | 23.5 (22.0–25.1)                                     | 15.6 (15.4–15.8)                                     | 15.7(15.5–15.9)                                      |
| 2 years                   | 17.2 (15.7–18.8)                                     | 30.9 (29.1–32.7)                                     | 20.6 (20.3–20.8)                                     | 20.7(20.5–20.9)                                      |
| 3 years                   | 20.6(18.9–22.3)                                      | 36.8 (34.8–38.7)                                     | 24.2 (23.9–24.4)                                     | 24.4(24.1–24.6)                                      |
| 4 years                   | 23.7 (21.9–25.6)                                     | 40.8 (38.7–43.0)                                     | 27.0 (26.8–27.3)                                     | 27.2(27.0–27.5)                                      |
| 5 years                   | 26.6 (24.6–28.6)                                     | 44.1 (41.8–46.3)                                     | 29.3 (29.1–29.6)                                     | 29.6 (29.3–29.9)                                     |
associated with lower LTFU included: receiving care at tertiary versus primary-care clinics (aHR 0.61, 95% CI 0.56 to 0.67), attending clinics with integrated adult and adolescent services and food rations (aHR 0.93, 95% CI 0.89 to 0.97), versus clinics without integrated services (but with food rations), and clinics having group adherence counselling (aHR 0.61, 95% CI 0.57 to 0.67), and patient support groups (aHR 0.77, 95% CI 0.66 to 0.90), versus not having these services. Interestingly, availability of peer educator programmes was associated with higher hazard of LTFU (aHR 1.25, 95% CI 1.18 to 1.31) as

Table 3. Cause-specific hazard model of patient and site-level correlates of LTFU after ART initiation among all patients, YA, OA and adults

| Predictor                          | All patients | Young adolescents | Older adolescents | Adults |
|-----------------------------------|--------------|-------------------|-------------------|--------|
|                                   | aHR (95% CI) | aHR (95% CI)      | aHR (95% CI)      | aHR (95% CI) |
| Patient-level characteristics     |              |                   |                   |         |
| Age group                         |              |                   |                   |         |
| Young adolescents                 | 0.77 (0.69 to 0.86) | -                  | -                  | -       |
| Older adolescents                 | 1.54 (1.41 to 1.68) | 1.00               | 1.00               | 1.00    |
| Adults                            | 1.00         |                   |                   |         |
| Sex, pregnancy status             |              |                   |                   |         |
| Males                             | 1.00         |                   |                   | 1.00    |
| Nonpregnant females               | 0.90 (0.88 to 0.93) | 1.51 (1.27 to 1.80) | 0.89 (0.86 to 0.92) | n/s     |
| Pregnant females                  | 1.20 (1.14 to 1.27) | 2.42 (1.98 to 2.95) | 1.17 (1.10 to 1.24) | n/s     |
| CD4 count at ART start (cells/µL) |              |                   |                   |         |
| <100                              | 1.02 (0.96 to 1.07) | n/s                | n/s                | 1.02 (0.97 to 1.08) |
| 100 to 199                        | 0.86 (0.81 to 0.90) | 0.86 (0.81 to 0.91) | 0.81 (0.77 to 0.86) | n/s     |
| 200 to 349                        | 0.82 (0.77 to 0.86) | 0.81 (0.77 to 0.86) | n/s                | n/s     |
| ≥350                              | 1.00         |                   |                   | 1.00    |
| WHO stage at ART start            |              |                   |                   |         |
| Stages I to II                    | 1.00         | 1.00              |                   | 1.00    |
| Stages III to IV                  | 1.32 (1.28 to 1.36) | 1.34 (1.11 to 1.61) |                   | 1.33 (1.29 to 1.37) |
| Year of ART initiation            |              |                   |                   |         |
| 2000 to 2004                      | 1.00         | 1.00              |                   | 1.00    |
| 2005 to 2009                      | 0.97 (0.89 to 1.06) | 0.81 (0.58 to 1.13) |                   | 0.98 (0.90 to 1.07) |
| 2010 to 2012                      | 1.27 (1.17 to 1.39) | 1.21 (0.84 to 1.74) |                   | 1.29 (1.17 to 1.41) |
| 2013 to 2014                      | 1.19 (1.06 to 1.32) | 3.43 (2.04 to 5.78) |                   | 1.21 (1.08 to 1.35) |
| Site-level characteristics        |              |                   |                   |         |
| Programme                         |              |                   |                   |         |
| AMPATH                            | 1.00         | 1.00              |                   | 1.00    |
| FACES                             | 0.93 (0.86 to 0.99) | 0.46 (0.33 to 0.66) | 0.48 (0.40 to 0.58) | 0.94 (0.88 to 1.01) |
| MASAKA                            | 0.96 (0.77 to 1.18) | 0.43 (0.28 to 0.66) | 0.59 (0.46 to 0.76) | 0.92 (0.74 to 1.14) |
| MTCT-PLUS                         | 0.43 (0.35 to 0.52) | n/s               | 0.11 (0.02 to 0.78) | 0.43 (0.35 to 0.53) |
| NACP                              | 3.49 (3.02 to 4.03) | 2.10 (0.61 to 2.76) | 1.26 (0.96 to 1.66) | 3.43 (2.96 to 3.98) |
| RAKAI                             | 0.34 (0.25 to 0.45) | 0.31 (0.04 to 2.18) | 0.46 (0.25 to 0.83) | 0.32 (0.24 to 0.43) |
| Level of care                     |              |                   |                   |         |
| Primary                           | 1.00         | n/s               | n/s                | 1.00    |
| Secondary                         | 1.09 (1.05 to 1.14) | 1.09 (1.04 to 1.14) |                   |         |
| Tertiary                          | 0.61 (0.56 to 0.67) |                   |                   | 0.62 (0.57 to 0.67) |
| Clinic setting and nutritional support |          |                   |                   |         |
| Integrated clinics with food rations | 0.93 (0.89 to 0.97) | n/s               | n/s                | 0.93 (0.89 to 0.98) |
| Integrated clinics without food rations | 1.02 (0.92 to 1.14) | n/s               | n/s                | 1.04 (0.94 to 1.17) |
| Separate clinics with food rations | 1.00         |                   |                   | 1.00    |
| Support groups                    | 0.77 (0.66 to 0.90) | n/s               | n/s                | 0.77 (0.65 to 0.90) |
| Group adherence counselling       | 0.61 (0.57 to 0.67) | n/s               | n/s                | 0.62 (0.57 to 0.67) |
| Peer educator programme           | 1.25 (1.18 to 1.31) | n/s               | n/s                | 1.24 (1.18 to 1.31) |
| Outreach of patients missing visits | 1.25 (1.20 to 1.39) | n/s               | n/s                | 1.25 (1.12 to 1.39) |

n/s, variable not statistically significant, excluded from multivariable model; aHR, adjusted hazard ratios; ART, antiretroviral therapy; CI, confidence interval; LTFU, loss to follow-up
was having outreach programmes for missed visits, (aHR 1.25, 95% CI 1.20 to 1.39), compared to sites which did not have these programmes.

Results from age-specific analyses for the YA, OA and adult populations are also shown in Table 3. Among OA, the hazard of LTFU was primarily driven by pregnant adolescents compared to adolescent males (aHR 2.42, 95% CI 1.98 to 2.95). Also among OA, in contrast to adolescent females, nonpregnant female adolescents had higher LTFU (aHR 1.51, 95% CI 1.27 to 1.80) compared to adolescent males. The variation with respect to programme of attendance among OA, YA and adults were consistent with those seen in the overall study population as described above. The correlates of LTFU among YA were similar to those observed in the overall study population, as described above.

4 | DISCUSSION

This analysis highlights the significantly higher LTFU after ART initiation among OA as compared to either YA or adults and is one of the first to identify the significant impact of pregnancy on LTFU among OA. Individual and structural reasons for such LTFU identified in the literature could be amplified among OA due to limited autonomy and resources to independently continue ART. Our findings are in line with recent reports which suggest pregnancy at ART initiation is a significant risk factor for LTFU and that postnatal disengagement from ART services is a significant programmatic challenge. Our observations imply that pregnant OA initiating ART should be one of the key populations targeted for interventions to reduce LTFU in prevention of mother-to-child HIV transmission (PMTCT) programmes. Also notably, OA had the highest proportion of women pregnant at ART initiation, suggesting low rates of HIV testing or prior awareness of HIV positive status and/or recent HIV infections. This signals opportunities to intervene prior to early sexual encounters that result in pregnancy and HIV and to engage adolescents in health care prior to pregnancy and HIV. Many pregnant OA may be starting ART soon after learning their HIV positive status, which in turn may impact ART retention as they deal with adjusting to the new diagnosis and lifelong treatment. In contrast to adults where nonpregnant female patients had lower hazard of LTFU compared to males, older adolescent girls who were not pregnant had over 50% higher hazard for LTFU compared to males. This suggests that, regardless of pregnancy status, adolescent girls should be included in key populations targeted for retention interventions.

We observed a worsening trend for LTFU among participants initiating ART in more recent years. This could mean inadequate ART retention in the face of significant scale-up of ART services, and reflect challenges within health systems overwhelmed by an ever-increasing ART population. It wasn’t possible to account for undocumented transfers to other health facilities: this could have applied to some adolescents transitioning to adult care elsewhere. However, we expect that this would be a small proportion as all the health facilities in the analysis offered adolescent and adult care. Therefore, reasons for LTFU deserve additional qualitative exploration, particularly focusing ART access barriers and enablers for the pregnant OA population.

LTFU varied widely by programme in our analysis, which may reflect the impact of combination of programme-specific characteristics, and the standard of care provided. Overall and by age-group, LTFU was significantly lower at tertiary institutions. This may be a reflection of better resources typically provided at such institutions but is a concern in the wake of rapid ART-scale up and decentralization to primary health facilities. Our analysis also highlighted the importance of caring for adolescents and adults in integrated clinics. This is likely due to elimination of the “adult transition” step, which facilitates continued care and retention of adolescent records. While there is value in dedicated adolescent clinics, the transition period can prove a vulnerable point for LTFU. On the other hand, food support appeared to be a strong factor associated with reduction of LTFU among adults but not among adolescents (where integration of services was the main factor associated with reduced rates of LTFU). This is consistent with other studies on the subject and possibly delineates the different priorities and structural barriers to retention in these two age groups.

Although peer educator and outreach programmes are expected to be associated lower LTFU after ART initiation, this association was not observed among adults or adolescent ART programmes. Paradoxically, health facilities with these services had higher adult LTFU, and we cannot exclude the potential for reverse causality – perhaps sites which already had high LTFU preferentially implemented peer educator and outreach programmes to address patient retention issues in their programme.

The major strength of this study was the use of programmatic cohorts drawn from diverse real-world clinical settings in East Africa, which making our findings generalizable to routine ART service delivery in our context. At the same time, our analysis has a number of limitations, including potential outcome misclassification as the result of passive collection of mortality data and incomplete documentation of “silent” transfer. Additionally, we determined LTFU at the time of database closure which could overestimate LTFU among participants newly initiating ART, as patients with longer ART observation times could have become disengaged and re-engaged in care without being classified as LTFU. Finally, we had limited data on pregnant YA, and we only examined the impact of pregnancies at ART initiation (excluding pregnant women who initiated ART solely for PMTCT), and did not account for pregnancies occurring during ART follow-up, all of which may have underestimated LTFU due to pregnancy. Despite these limitations, our analysis provides useful insights into the outcomes of the burgeoning adolescent population in our setting and describes a nuanced picture of LTFU correlates. These data can inform public health programmes to ensure the continuity and success of ART.

5 | CONCLUSION

OA initiating ART experienced the highest rates of LTFU when compared to YA and adults. Among the OA, females (pregnant or not) had particularly high risk of being LTFU. This analysis
highlights the need to develop, test and assess interventions designed to retain older adolescents on ART, particularly girls and women initiating ART while pregnant.

**AUTHORS’ AFFILIATIONS**

1 Mailman School of Public Health, ICAP at Columbia University, New York, NY; 2 Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY; 3 Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; 4 Fairbanks School of Public Health, Indiana University, Indianapolis, IN; 5 School of Medicine, Indiana University, Indianapolis, IN; 6 Academic Model Providing Access to Healthcare (AMPATH), Moi University, Eldoret, Kenya; 7 Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD; 8 Ocean Road Cancer Institute, Dar es Salaam, Tanzania; 9 Masaka Regional Referral Hospital, Masaka, Uganda; 10 Vagelos College of Physicians and Surgeons, Columbia University, New York, NY

**COMPETING INTERESTS**

None. The authors report no conflicts of interest.

**AUTHORS’ CONTRIBUTIONS**

HNB, BE, ANK, CTY, KWK and EJA contributed to the conception of the analysis idea; BSM, ANK, HNB, CTY, SA, HF, EL and JS contributed to data collection and cleaning; ANK, BSM and CTY analysed the data; HNB, BE, ANK and CTY wrote the manuscript; HNB, BE, ANK, CTY, KWK, BSM, EJA, SA, HW, EL and JS reviewed and contributed to the manuscript; BE gave overall technical oversight for the analytic process and manuscript writing.

**ACKNOWLEDGEMENTS**

The authors acknowledge the patients and healthcare workers at participants. This work is supported by the IeDEA East Africa Collaboration. We would like to acknowledge the sites and the site principal investigators who contributed data to this analysis: Kenya: Academic model providing Access to Healthcare, S. Ayaya; Family AIDS Care and Education Services, E. Bukuasi; MTCT-plus Nyanya Provincial Hospital, J. Otsieno; Tanzania: National AIDS Control Program, G. Somi; Morogoro Regional Hospital, R. Lyamuya; Tumbi Regional Hospital, N. Kapella, National Institute for Medical Research Kisessa Clinic, M. Urassa, Uganda: Masaka Regional Referral Hospital, J. Ssali; Rakai Health Science Program, F. Nalugoda, MTCT-plus St. Francis Nsambya, P. Okong, MTCT-plus Mulago D. Wabwire.

**Funding**

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Cancer Institute (NCI), in accordance with the regulatory requirements of the National Institutes of Health under the following grant numbers: U01AI069911 (East Africa IeDEA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**REFERENCES**

1. United Nations Children’s Education Fund (UNICEF). For every child, end AIDS. Seventh Stock Taking Report. 2016.
2. United Nations. Youth population trends and sustainable development. Population Facts. 2015;2015(1):1.
3. UNAIDS. Ending AIDS, Progress towards the 90-90-90 targets. Global AIDS Update. 2017;2017:25.
4. Labar MJ, Favorose R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi V, Alwar T, et al. High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care. AIDS. 2014;28(4):559–58.
5. Shroff A, Gungwu H, Dixon M, Nyathi M, Ndebele W, Saint-Sauveur JF, et al. HIV-infected adolescents in southern Africa can achieve good treatment outcomes: results from a retrospective cohort study. AIDS. 2013;27(12):1971–8.
6. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51(1):65–71.
7. Bakanda C, Birungi J, Mweesigwa R, Nachega JB, Chan K, Palmer A, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS ONE. 2011;6(4):e19261.
8. Karageanes E, Bila D, Augusto O, Lain M, Muenga B, Mukanja C, et al. Uptake and retention in care of pregnant women starting option B+ in Maputo, in Conference on Retroviruses and Opportunistic Infections (CROI). Seattle: 2017.
9. Kaplan S, Oosthuizen C, Stinson K, Little F, Elvrad J, Osel M, et al. Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa, in Conference on Retroviruses and Opportunistic Infections (CROI). Seattle: 2017.
10. Tentah L, Haas AD, Twaey H, Jahn A, van Oosterhout JJ, Chimwabwanda F, et al. Retention in care during the first three years of antiretroviral therapy for women in Malawi’s option B+ programme: an observational cohort study. Lancet HIV. 2016;3(4):e175–82.
11. Domenico JW, Puttkammer N, Young P, Yuhas K, Francois K, GrandPierre R, et al. Attrition from antiretroviral treatment services among pregnant and non-pregnant patients following adoption of Option B+ in Haiti. Glob Health Action. 2017;10(1):1330915.
12. Hodgson I, Plummer ML, Konopka SN, Colvin CJ, Jonas E, Albertini J, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS ONE. 2014;9(11):e111421.
13. International epidemiologic Databases to Evaluate AIDS (IeDEA). Internationalepidemiologic Databases to Evaluate AIDS (IeDEA) 2018 [cited 2018 Jun 16]. Available from: https://www.iedea.org/regions/east-africa/
14. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, et al. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc. 2014;17:19045.
15. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access, Recommendations for a public health approach. In: WHO, editor. HIV/AIDS Programme: strengthening health services to fight HIV/AIDS. Geneva: WHO; 2006.
16. World Health Organisation (WHO). Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings; towards universal access, Recommendations for a public health approach. In: World Health Organisation (WHO), editor. HIV/AIDS Programme: strengthening health services to fight HIV/AIDS. Geneva: World Health Organisation (WHO); 2010.
17. Aalen O, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141–50.
18. Colvin CJ, Konopka S, Chalker JC, Jonas E, Albertini J, Amal A, et al. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women. PLoS ONE. 2014;9(10):e108150.
19. van Lettow M, Bedell R, Mayuni I, Mateyu G, Landes M, Chan AK, et al. Towards elimination of mother-to-child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+). J Int AIDS Soc. 2014;17:18994.
20. Phillips T, Thebus E, Bekker LG, McIntyre J, Abrams EJ, et al. Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study. J Int AIDS Soc. 2014;17:19242.
21. Phillips T, McNairy ML, Zerbe A, Myer L, Abrams EJ. Implementation and operational research: postpartum transfer of care among HIV-infected women initiating antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2015;73(3):e102–9.
22. Geng EH, Odeny TA, Lyamuya RE, Nakiwogga-Muwanga A, Diero L, Bwana M, et al. Estimation of Mortality among HIV-infected people on antiretroviral therapy in eastern Africa: a sampling based approach in an observational, multisite, cohort study. Lancet HIV. 2015;2(3):e107–16.
24. Dahourou DL, Gautier-Lafaye C, Teasdale CA, Renner L, Yotebieng M, Desmonde S, et al. Transition from paediatric to adult care of adolescents living with HIV in sub-Saharan Africa: challenges, youth-friendly models, and outcomes. J Int AIDS Soc. 2017;20 Suppl 3:34–49.
25. Davies MA, Tsondai P, Tiffin N, Eley B, Rabie H, Euvrard J, et al. Where do HIV-infected adolescents go after transfer? – Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform. J Int AIDS Soc. 2017;20 Suppl 3:16–24.
26. Fayorsey RN, Saito S, Carter RJ, Gusmao E, Frederix K, Koech-Keter E, et al. Decentralization of pediatric HIV care and treatment in five sub-Saharan African countries. J Acquir Immune Defic Syndr. 2013;62(5):e124–30.
27. Reidy WJ, Sheriff M, Wang C, Hawken M, Koech E, Elul B, et al. Decentralization of HIV care and treatment services in Central Province, Kenya. J Acquir Immune Defic Syndr. 2014;67(1):e34–40.
28. Cluver LD, Toska E, Orkin FM, Meinck F, Hodes R, Yakubovich AR, et al. Achieving equity in HIV-treatment outcomes: can social protection improve adolescent ART-adherence in South Africa? AIDS Care. 2016;28 Suppl 2:73–82.
29. Fetzer BC, Mupenda B, Lusiama J, Kitetele F, Golin C, Behets F. Barriers to and facilitators of adherence to pediatric antiretroviral therapy in a sub-Saharan setting: insights from a qualitative study. AIDS Patient Care STDS. 2011;25(10):611–21.
30. Hardon AP, Akurut D, Comoro C, Ekozie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.
31. Teasdale CA, Akwar T, Chege D, Fayorsey R, Hawken MP, Abrams EJ. Impact of youth and adolescent friendly services on retention of 10-24-Year-olds in HIV care and treatment programs in Nyanza, Kenya. J Acquir Immune Defic Syndr. 2016;71(2):e56–9.
32. Keane J, Pharr JR, Buttner MP, Ezeanolue EE. Interventions to reduce loss to follow-up during all stages of the HIV care continuum in sub-Saharan Africa: a systematic review. AIDS Behav. 2017;21(6):1745–54.
33. Chaiyachati KH, Ogboju O, Price M, Suthar AB, Negussie EK, Barninghausen T. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS. 2014;28 Suppl 2:S187–204.
34. Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review. AIDS Care. 2015;27(7):805–16.
35. Nuwagaba-Biribonwoha H, Jakubowski A, Mugisha V, Basinga P, Asiimwe A, Nash D, et al. Low risk of attrition among adults on antiretroviral therapy in the Rwandan national program: a retrospective cohort analysis of 6, 12, and 18 month outcomes. BMC Public Health. 2014;14:889.
36. Johnson LF, Estill J, Keiser O, Cornell M, Moolla H, Schomaker M, et al. Do increasing rates of loss to follow-up in antiretroviral treatment programs imply deteriorating patient retention? Am J Epidemiol. 2014;180(12):1208–12.